Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

NCT06761976 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Advanced Non-small Cell Lung Cancer
Cancer

Interventions

DRUG: Sevabertinib

Sponsor

Bayer